Pinpoint Genomics

In marketing its newly launched Pervenio lung cancer prognostic test, Life Technologies' sales force is targeting specialist thoracic surgeons and medical oncologists in 48 US states.

Life Technologies this week launched Pervenio Lung RS – a quantitative PCR-based assay for lung cancer prognosis that gauges the expression of 14 genes – through its CLIA lab in Sacramento, Calif.

This story has been updated from a previous version to include additional information about the QuantStudio Dx platform.

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.

By Tony Fong
NEW YORK (GenomeWeb News) – Genetic test maker Pinpoint Genomics has moved into commercialization phase with the launch of its first product, a prognostic test for non-small cell lung cancer.

Roche said this week that its Cobas CT/NG test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.